The Experts below are selected from a list of 186 Experts worldwide ranked by ideXlab platform

Ariful Basher - One of the best experts on this subject based on the ideXlab platform.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.
    BMC research notes, 2018
    Co-Authors: Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, Be-nazir Ahmed, Dinesh Mondal, A. F. M. Akhtar Hossain, Ariful Basher
    Abstract:

    Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
    BMC, 2018
    Co-Authors: Md Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, A. Akhtar F. M. Hossain, Be-nazir Ahmed, Dinesh Mondal, Ariful Basher
    Abstract:

    Abstract Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B Deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B Deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B Deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B Deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh

Golam Hasnain - One of the best experts on this subject based on the ideXlab platform.

Shah Golam Nabi - One of the best experts on this subject based on the ideXlab platform.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.
    BMC research notes, 2018
    Co-Authors: Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, Be-nazir Ahmed, Dinesh Mondal, A. F. M. Akhtar Hossain, Ariful Basher
    Abstract:

    Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
    BMC, 2018
    Co-Authors: Md Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, A. Akhtar F. M. Hossain, Be-nazir Ahmed, Dinesh Mondal, Ariful Basher
    Abstract:

    Abstract Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B Deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B Deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B Deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B Deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh

Proggananda Nath - One of the best experts on this subject based on the ideXlab platform.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.
    BMC research notes, 2018
    Co-Authors: Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, Be-nazir Ahmed, Dinesh Mondal, A. F. M. Akhtar Hossain, Ariful Basher
    Abstract:

    Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
    BMC, 2018
    Co-Authors: Md Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, A. Akhtar F. M. Hossain, Be-nazir Ahmed, Dinesh Mondal, Ariful Basher
    Abstract:

    Abstract Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B Deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B Deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B Deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B Deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh

Dinesh Mondal - One of the best experts on this subject based on the ideXlab platform.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.
    BMC research notes, 2018
    Co-Authors: Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, Be-nazir Ahmed, Dinesh Mondal, A. F. M. Akhtar Hossain, Ariful Basher
    Abstract:

    Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh.

  • Amphotericin B Deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
    BMC, 2018
    Co-Authors: Md Golam Hasnain, Proggananda Nath, Shomik Maruf, Shah Golam Nabi, A. Akhtar F. M. Hossain, Be-nazir Ahmed, Dinesh Mondal, Ariful Basher
    Abstract:

    Abstract Objective Based on studies in India (as there was no studies from outside India) amphotericin B Deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B Deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B Deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B Deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B Deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B Deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B Deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh